LONDON – Quanta Dialysis Technologies Ltd. has raised £38 million (US$46.7 million) in the first close of a series C round, to fund a U.S. FDA 510(k) submission and U.K. commercial launch of its SC+ home hemodialysis system. With the cash now in hand, both these events are due to occur before the end of 2019. "We've got a lot of work to do," said John Milad, CEO of Quanta. "This is the rocket fuel."

It has been a few years since there was an active market for digital health IPOs. But that's changed now. Chronic health care management company Livongo Health Inc. has raised $355 million in an IPO, following last month's $609 million public debut for health care workflow management software company Change Healthcare Inc.

With the ongoing push toward value-based care, providers are looking for ways to improve patient outcomes while also lowering health care costs. Los Angeles-based Dearhealth Inc.'s artificial intelligence-powered software-as-a-service (SaaS) platform aims to do meet that demand by helping physicians better manage patients with chronic conditions. Now Philips Health Technology Ventures and other large investors are putting their money behind the company, seeing an opportunity to generate real movement in advance population health.

Xealth Inc., of Seattle, closed a series A financing with an additional $3 million from new investors Atrium Health, Cleveland clinic and Memorialcare Innovation Fund. The proceeds, which now total $14 million, will go toward further developing and deploying the company's digital prescribing and analytics platform. The company focuses on helping health systems organize and utilize digital health tools to optimize workflow, patient engagement and financial results.

Philadelphia-based Healthverity Inc. reported it closed a $25 million series C investment round led by existing investor Foresite Capital. Other major investors included Flare Capital Partners and Greycroft. The new investments bring Healthverity's total venture capital funding to $42.3 million and will be used to further develop the company's health care data platform and expand its marketing.